ciclesonide nasal aerosol + ciclesonide nasal spray

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Perennial Allergic Rhinitis

Conditions

Perennial Allergic Rhinitis

Trial Timeline

Sep 1, 2012 โ†’ Jul 1, 2013

About ciclesonide nasal aerosol + ciclesonide nasal spray

ciclesonide nasal aerosol + ciclesonide nasal spray is a approved stage product being developed by Sumitomo Pharma for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01654536. Target conditions include Perennial Allergic Rhinitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01654536ApprovedCompleted

Competing Products

20 competing products in Perennial Allergic Rhinitis

See all competitors
ProductCompanyStageHype Score
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
77
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
77
ciclesonide + mometasoneSumitomo PharmaPhase 3
77
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
ciclesonide HFA 160 ฮผgSumitomo PharmaPhase 3
77
Budesonide + PlaceboAstraZenecaApproved
85
Ciclesonide + PlaceboAstraZenecaPhase 3
77
CiclesonideAstraZenecaPhase 3
77
CiclesonideAstraZenecaPhase 3
77
Ciclesonide nasal + PlaceboAstraZenecaPhase 3
77
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
85
CiclesonideAstraZenecaPhase 3
77
MK-8237 tablets + Placebo tablets + Rescue Medication: Self-Injectable Epinephrine + Rescue Medication: Loratadine tablets + Rescue Medication: Olopatadine ophthalmic drops + Rescue Medication: Mometasone furoate nasal sprayMerckPhase 3
77
Placebo + Montelukast + Fluticasone propionateMerckApproved
85
montelukast + placeboMerckApproved
85
MK-8237 6 DU + MK-8237 12 DU + PlaceboMerckPhase 1
33
loratadine + loratadine + loratadineMerckApproved
85